Exagen Inc. reported a revenue increase of 11.7% for the first quarter of 2026, generating $17.3 million compared to $15.5 million in the same period of 2025. This growth was primarily driven by an increase in the average selling price (ASP) of its AVISE® CTD tests, which rose to $444 per test from $419, alongside a 10% increase in the number of tests delivered. Despite the revenue growth, the company recorded a net loss of $4.0 million, slightly higher than the $3.8 million loss reported in the prior year. The increase in losses was attributed to higher interest expenses and changes in the fair value of warrant liabilities.
In terms of operational metrics, Exagen's total assets decreased to $52.0 million as of March 31, 2026, down from $58.0 million at the end of 2025. The company's cash and cash equivalents also fell to $21.5 million from $32.2 million, reflecting ongoing cash burn and increased accounts receivable. The company’s accumulated deficit reached $318.2 million, indicating the financial challenges it continues to face. Exagen's workforce increased, with 24.1 million shares outstanding as of March 31, 2026, up from 22.9 million at the end of 2025.
Strategically, Exagen has focused on enhancing its product offerings, particularly through the introduction of new biomarkers for its AVISE® CTD tests. The company has also revitalized its leadership team, which includes experienced professionals in diagnostics and medical technology. This restructuring aims to improve operational efficiency and drive revenue growth. The company is actively pursuing partnerships with pharmaceutical companies and academic institutions to leverage its testing capabilities and data.
Looking ahead, Exagen anticipates continued revenue growth driven by the adoption of its new biomarkers and an expanding customer base. However, the company acknowledges the need for additional funding to support its operations and growth strategy, particularly as it continues to incur losses. Management believes that existing capital resources will be sufficient to meet obligations for at least the next twelve months, but additional financing may be necessary to sustain operations and pursue growth initiatives. The company remains committed to improving its financial performance and achieving profitability in the long term.
About EXAGEN INC.
Exagen Inc. is a medical technology company specializing in autoimmune disease diagnostics. Its flagship AVISE® tests aid in the differential diagnosis, prognosis, and monitoring of complex rheumatic conditions like lupus and rheumatoid arthritis. The company leverages proprietary biomarkers and advanced assays to improve diagnostic accuracy, reduce healthcare costs, and support personalized treatment, primarily serving rheumatologists and healthcare providers in the U.S. through specialized laboratory services and innovative, clinically validated testing solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.